WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530019
CAS#: 146731-14-8 (sodium)
Description: Z-335 Salt is a thromboxane A2 receptor antagonist potentially for the treatment of arterial occlusive disease.
Hodoodo Cat#: H530019
Name: Z-335 sodium
CAS#: 146731-14-8 (sodium)
Chemical Formula: C18H17ClNNaO4S
Exact Mass: 0.00
Molecular Weight: 401.840
Elemental Analysis: C, 53.80; H, 4.26; Cl, 8.82; N, 3.49; Na, 5.72; O, 15.93; S, 7.98
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 146737-36-2 (Free acid) 146731-14-8(sodium)
Synonym: Z-335; Z335; Z 335
IUPAC/Chemical Name: sodium 2-(2-(((4-chlorophenyl)sulfonamido)methyl)-2,3-dihydro-1H-inden-5-yl)acetate
InChi Key: UEPBEZPJELQKJV-UHFFFAOYSA-M
InChi Code: InChI=1S/C18H18ClNO4S.Na/c19-16-3-5-17(6-4-16)25(23,24)20-11-13-8-14-2-1-12(10-18(21)22)7-15(14)9-13;/h1-7,13,20H,8-11H2,(H,21,22);/q;+1/p-1
SMILES Code: O=C([O-])CC1=CC2=C(CC(CNS(=O)(C3=CC=C(Cl)C=C3)=O)C2)C=C1.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 146737-36-2(Z-335 Free base) 146731-14-8(Z-335 Salt)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 401.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Yoshida M, Sato Y, Shimura T, Ohkubo S, Honma S, Tanaka T, Kurimoto T, Nakahata N. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology. 2007;79(1):50-6. PubMed PMID: 17139194.
2: Kawabata Y, Kamada E, Furuta S, Takei M, Kurimoto T, Okudaira K, Nishigaki R. ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles. Pharm Res. 2004 Mar;21(3):467-75. PubMed PMID: 15070098.
3: Matsuno H, Uematsu T, Niwa M, Kozawa O, Nagashima S, Kohno K, Kato H, Kawabata Y, Yoshida Y, Kanamaru M. Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90. PubMed PMID: 12092745.
4: Kawabata Y, Nakamura H, Kamada E, Furuta S, Shinozaki Y, Kurimoto T, Nishigaki R. Mechanism of hepatobiliary transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335), and its xenobiotic taurine conjugate (Z-335-Tau) in rats. J Pharm Sci. 2003 Jan;92(1):67-76. PubMed PMID: 12486683.
5: Kawabata Y, Furuta S, Shinozaki Y, Kurimoto T, Nishigaki R. Carrier-mediated active transport of a novel thromboxane A(2) receptor antagonist [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) into rat liver. Drug Metab Dispos. 2002 May;30(5):498-504. PubMed PMID: 11950778.
6: Tanaka T, Sato R, Kurimoto T. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur J Pharmacol. 2000 Aug 11;401(3):413-8. PubMed PMID: 10936501.
7: Tanaka T, Fukuta Y, Fukuda Y, Higashino R, Ito S, Takei M, Tamaki H, Kurimoto T, Suzuki Y. Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats. Biol Pharm Bull. 1999 Dec;22(12):1382-4. PubMed PMID: 10746175.
8: Tanaka T, Fukuta Y, Higashino R, Sato R, Nomura Y, Fukuda Y, Ito S, Takei M, Kurimoto T, Tamaki H. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Eur J Pharmacol. 1998 Sep 11;357(1):53-60. PubMed PMID: 9788773.
9: Tanaka T, Ito S, Higashino R, Fukuta Y, Fukuda Y, Takei M, Kurimoto T, Tamaki H. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res. 1998 Sep 1;91(5):229-35. PubMed PMID: 9755835.
10: Saitoh T, Shibayama T. Removal and degradation of β-lactam antibiotics in water using didodecyldimethylammonium bromide-modified montmorillonite organoclay. J Hazard Mater. 2016 Nov 5;317:677-85. doi: 10.1016/j.jhazmat.2016.06.003. PubMed PMID: 27339949.
11: Wu L, Liu J, Zhang Y, Hou Y. Development of a HPLC/MS/MS method for simultaneous determination of tinidazole, dyclonine and chlorhexidine in rat plasma and its application in the pharmacokinetic research of a film-forming solution. J Pharm Biomed Anal. 2012 Mar 25;62:224-7. doi: 10.1016/j.jpba.2012.01.009. PubMed PMID: 22305084.
12: Shang DW, Wang ZZ, Ni XJ, Zhang M, Hu JQ, Qiu C, Wen YG. Development and validation of a sensitive LC-MS/MS assay for the quantification of nizatidine in human plasma and urine and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:80-7. doi: 10.1016/j.jchromb.2015.06.026. PubMed PMID: 26197435.
13: Gu W, Wang D, Pan Z, Liu X, Cai B, Chen J. Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. Biomed Chromatogr. 2016 Jul;30(7):1097-103. doi: 10.1002/bmc.3656. PubMed PMID: 26578094.
14: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. PubMed PMID: 14571286.
15: Li J, Miao F, Lin L, Zhu D, Lin C, Liu J. [Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. Zhongguo Zhong Yao Za Zhi. 2012 Mar;37(6):853-7. Chinese. PubMed PMID: 22715737.
16: Tang Y, Zhang S, Li X, Sun X, Wen N, Yu M, Peng L, Li J, Li Z, Li B. [Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. Se Pu. 2012 Feb;30(2):154-9. Chinese. PubMed PMID: 22679829.
17: Chen Q, Li P, Li B, Yuan F, Li X, Zhu J. Development of a method for comprehensive and quantitative analysis of armillarisin succinate ester in its medicinal preparations by liquid chromatography-ion trap mass spectrometry. Pharmazie. 2011 Sep;66(9):648-53. PubMed PMID: 22026118.
18: Sun C, Wu J, Wang D, Pan Y. Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR. J Pharm Biomed Anal. 2010 Feb 5;51(3):778-83. doi: 10.1016/j.jpba.2009.09.050. PubMed PMID: 19864105.
19: Xu Y, Si D, Liu C. Determination of strychnine and brucine in rat plasma using liquid chromatography electrospray ionization mass spectrometry. J Pharm Biomed Anal. 2009 Feb 20;49(2):487-91. doi: 10.1016/j.jpba.2008.10.020. PubMed PMID: 19062219.
20: Li L, Pabbisetty D, Carvalho P, Avery MA, Williamson JS, Avery BA. Ultra-performance liquid chromatography-tandem mass spectrometric method for the determination of Artemisinin in rat serum and its application in pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):131-7. doi: 10.1016/j.jchromb.2008.01.057. PubMed PMID: 18353736.
